Strides taken to establish a single continental Medicines Regulatory Agency in Africa


The African Medicines Agency (AMA) will be a single, fully-fledged continental medicines regulatory agency of the African Union, dedicated to assisting Member States to improve their capacities to regulate medical products and health technologies, and to continue to build on existing AMRH (African Medicines Regulatory Harmonization) initiatives. A single continental medicines regulatory agency can improve access to medicines to those most in need and disrupt the cycle of poverty on the African continent. However, in order for AMA to become a reality, all African Member States need to sign and ratify the AMA Treaty. The AMA Treaty was adopted by AU Assembly on February 11 2019.

A minimum of 15 Member States are needed to ratify the AMA Treaty in their national Parliaments for AMA to come into force. So far 17 countries have signed, out of which Burkina Faso, Mali and Rwanda have ratified. They are; Algeria, Benin, Burkina Faso, Chad, Gabon, Ghana, Guinea, Madagascar, Mali, Morocco, Niger, Rwanda, Saharawi Arab Republic, Senegal, Seychelles, Sierra Leone and Tunisia.

The AMA Treaty is open to signature by all AU Heads of State and Government and/or by Ministers of Foreign Affairs, either in person or by designation in writing to their Ambassador accredited to the African Union. Ratification processes vary by Member State, depending on whether legislative ratification or executive ratification applies.

AMA, once legally mandated by AU Member States (MS), will be an established organ of AU and will facilitate availability of quality, safe and efficacious medical products and health technologies on the continent. This will be achieved through co-ordinating national and regional regulatory systems for medical products, providing regulatory oversight of selected medical products as well as promoting co-operation, harmonisation and mutual recognition of regulatory decisions.

The Agency offers the opportunity for a continental focus for certain activities, such as the opportunity to assess special classes of medicines (e.g. advanced therapies), Active Pharmaceutical Ingredients (APIs) and products that are currently not well regulated in many African countries (IVDs and devices, traditional medical products). AMA will collaborate with Regional Economic Communities (RECs) and national medicines regulatory agencies in the identification of substandard and falsified medical products, and facilitate information sharing across countries with the goal of providing a better environment for legitimate manufacturers to flourish and improve local manufacturing of quality products.

The Agency offers an opportunity to catalyse financial and technical support from countries and undertake certain activities more efficiently, while at the same time consolidating the RECs’ initiatives. It is also expected to play a key role by working closely with the Africa-CDC and WHO on the evaluation of, and oversight for the use of medical countermeasures for public health emergencies. Continent-wide alignment of regulatory technical requirements and standards through AMA is likely to make Africa a more attractive market for the pharmaceutical sector for both research and development, as well as introduction of innovations. AMA further plays a critical role in catalysing trade in support of the African Continental Free Trade Area (AfCFTA).

“The African Medicines Agency will be a single, fully fledged continental medicines regulatory agency of the African Union, dedicated to assisting Member States to improve their capacities to regulate medical products and health technologies.” @Nepad_Agency

Subscribe to the M&G

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years, and we’ve survived right from day one thanks to the support of readers who value fiercely independent journalism that is beholden to no-one. To help us continue for another 35 future years with the same proud values, please consider taking out a subscription.

Special Reports
The Mail & Guardian works with select partners to produce paid-for stories that we believe may be of interest to our readers. For more information, see here.

Related stories

Position of the African Blood Regulators Forum on the use of Convalescent Plasma in Africa as a potential therapy for Covid-19

A potential treatment for Covid-19 is the transfusion of convalescent plasma collected from those who have recovered from into those who are still affected

Safe medicines key in Africa’s Covid-19 response

The decrease in the amount of time to register medicines has shown to significantly increase lives saved and expand access to essential health technologies

A decade of the AMRH initiative

Africa has made significant progress in harmonising technical requirements for registration of medical products and good manufacturing practice

DBSA acts directly

During the Covid19 crisis, The Development Bank of Southern Africa has adopted a solidarity approach in responding to the country’s rapidly developing needs

Almost 300 000 jobs are at risk

'It is totally unacceptable that a legitimate, taxpaying business sector should be taken to the brink of ruin in such a way'

Galaxy A21s captures imagination of the youth

Samsung's latest Galaxy A devices are loved by their users and provide a range of awesome features that are truly important to them

Ingonyama Trust Board moves to retrench staff

More than 50 workers at the Ingonyama Trust Board have been issued section 189 notices

No proof of Covid-19 reinfection, yet

Some people report testing positive for Covid-19 after initially having the disease and then testing negative. Scientists are still trying to understand if this means that reinfection is possible

press releases

Loading latest Press Releases…

The best local and international journalism

handpicked and in your inbox every weekday